Artiria Medical secures funding to improve stroke treatments

Neurovascular start-up Artiria Medical has raised a total of CHF 3.8 million to advance the clinical and regulatory deployment of its first product.

Globally, one in four people over age 25 will have a stroke in their lifetime. This disease most often leads to severe disabilities and death. Currently, the standard of care is based on a minimally invasive approach, using the patient’s arteries as an access route to reach the lesion and locally deliver life-saving treatments. However, this procedure can be very challenging, as the device navigation takes place in a dense network of tiny brain arteries. This complexity causes surgeons to lose significant and critical time before they can effectively deliver the therapy. Artiria‘s technology addresses this medical need with an elegant and innovative solution particularly well integrated into current clinical practice.

An EPFL spin-off located at the EPFL Innovation Park, Artiria Medical has announced that it secured a CHF 1.1 million bridge funding. A few weeks prior, the medtech start-up was awarded a CHF 2.7 million grant from the highly selective EIC accelerator program.

With this additional funding of CHF 3.8 million, Artiria will significantly advance the clinical and regulatory deployment of its first product. “We are thrilled to receive such a substantial grant from an extremely competitive program, probably one of the most challenging in Europe. This fantastic result would not have been possible without the strong commitment of our exceptional team.” said Guillaume Petit-Pierre, co-founder and Artiria’s CEO.

Swiss start-ups and SMEs currently have no access to the European Innovation Council’s (EIC) Accelerator funding programme. The Swiss Accelerator launched by Innosuisse fills the gap.